RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer Article (Faculty180)

cited authors

  • Koh, Siang-Boo B; Ross, Kenneth; Isakoff, Steven J; Melkonjan, Nsan; He, Lei; Matissek, Karina J; Schultz, Andrew; Mayer, Erica L; Traina, Tiffany A; Carey, Lisa A; Rugo, Hope S; Liu, Minetta C; Stearns, Vered; Langenbucher, Adam; Saladi, Srinivas Vino V; Ramaswamy, Sridhar; Lawrence, Michael S; Ellisen, Leif W

description

  • While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features of refractory TNBC through molecular analysis of primary chemoresistant TNBC specimens.

authors

publication date

  • 2021

published in

start page

  • 4883

end page

  • 4897

volume

  • 27